Search Within

Survivorship Research

Formats
  1. Journal Article (9005)
  2. Meeting Abstract (5248)
  3. Book Section (579)
  4. Review (366)
  5. Editorial (234)
  6. Research Letter (138)
  7. Conference Paper (104)
  8. Correspondence (92)
  9. Guidelines (90)
  10. Miscellaneous (78)
  11. Book Whole (30)
Groups
  1. Department of Medicine (9325)
  2. Population Sciences Research Program (5753)
  3. Solid Tumor Oncology Division (5244)
  4. Surgery (5200)
  5. Epidemiology and Biostatistics (3666)
  6. Division of Subspecialty Medicine (3268)

More Groups

People
  1. Clifford Hudis (905)
  2. Kenneth Offit (792)
  3. Michael Zelefsky (755)
  4. Sergio Giralt (702)
  5. Mark Robson (682)
  6. Joachim Yahalom (634)

More People

Years
  1. 2025 (384)
  2. 2024 (844)
  3. 2023 (892)
  4. 2022 (906)
  5. 2021 (922)
  6. 2020 (933)

More Years

Publications
  1. Journal of Clinical Oncology (1892)
  2. International Journal of Radiation Oncology, Biology, Physics (912)
  3. Blood (723)
  4. Annals of Surgical Oncology (602)
  5. Cancer (334)
  6. Cancer Research (333)

More Publications

Publishers
  1. Elsevier Inc. (2394)
  2. American Society of Clinical Oncology (2041)
  3. Springer (1558)
  4. Wiley Blackwell (817)
  5. Oxford University Press (792)
  6. American Society of Hematology (790)

More Publishers

Results (15964)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Very low dose radiotherapy (VLDRT) with 4 Gy for potentially-curable indolent non-Hodgkin lymphomas
    Meeting Abstract

    Mankuzhy, N. P.; Imber, B. S.; Pammer, P.; Fregonese, B.; Cajo, A.; Cederquist, G.; Dreyfuss, A.; Lapen, K.; Patel, R. R.; Moore, Z. R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • When can we define cure after CAR-T therapy in LBCL? insights from serial landmark analyses
    Meeting Abstract

    Gomez-Llobell, M.; Shouval, R.; Brown, S.; Accav, N. G.; Devlin, S. M.; Corona, M.; Rejeski, K.; Rivas-Delgado, A.; Luna, A.; Luttwak, E.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Patterns of immune reconstitution and their clinical significance in aggressive lymphoma treated with CAR-T therapy
    Meeting Abstract

    Luan, D. Y.; Dewolf, S.; Fei, T.; Raj, S. S.; Shah, G. L.; Lareau, C.; Alhomoud, M.; Salles, G.; Rivas-Delgado, A.; Rejeski, K.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A phase 1b study of step-up dosing with ABBV-383, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Mian, H.; Baljevic, M.; Magen, H.; Gatt, M. E.; Mazza, I. A.; Searle, E.; Lichtman, E. I.; McKay, J. T.; Plesner, T.; Rodriguez, C.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Impact of absolute lymphocyte count at pre-apheresis and pre-lymphodepletion on chimeric antigen receptor (CAR)-T therapy outcomes in relapsed refractory multiple myeloma (RRMM)
    Meeting Abstract

    Nishimura, N.; Mailankody, S.; Brown, S.; Devlin, S. M.; Costa, B. A.; Farzana, T.; Jurgens, E. M.; Firestone, R. S.; Nath, K.; Chung, D. J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Devimistat results in a low complete remission rate in heavily pre-treated Burkitt lymphoma
    Meeting Abstract

    Steiner, R.; Nikolaenko, L.; Kambhampati, S.; Khan, N.; Nair, R.; Abramson, J. S.; Horwitz, S.; Matasar, M.; Owens, C.; Rodriguez Rivera, I. I.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • CAR-tography: Longitudinal mapping of CAR-T toxicities across B-cell malignancies reveals biologically distinct and prognostically relevant toxicity phenotypes
    Meeting Abstract

    Rejeski, K.; Fei, T.; Luna, A.; Alhomoud, M.; Valtis, Y. K.; Nishimura, N.; Gomez-Llobell, M.; Accav, N. G.; Beyar-Katz, O.; Raj, S. S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Barriers to immune effector cell therapy: Rapid disease progression, concern for toxicity, and lack of appropriate trials drive non-receipt after referral at a large academic center
    Meeting Abstract

    Valtis, Y. K.; Chin, K. K.; Yisraeli Salman, M.; Boussi, L.; Cadzin, B.; McLoughlin, C.; Cathcart, E.; Davis, P.; Brooklyn, C.; Goldstein, T.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Phase II study of longitudinal geriatric assessment with risk-adapted interventions to reduce non-relapse mortality in allogeneic hematopoietic cell transplantation for older patients with advanced myeloid malignancies
    Meeting Abstract

    Lin, R. J.; Kim, S. J.; Brown, S.; Hanley, D. M.; Engstler, D. E.; Politikos, I.; Gyurkocza, B.; Tamari, R.; Papadopoulos, E. B.; Saldia, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • The Composite Health Risk Assessment Model (CHARM) predicts risks of toxicities, functional and cognitive decline among survivors of allogeneic hematopoietic cell transplantation (allo-HCT): A prospective BMT-CTN study 1704
    Meeting Abstract

    Sorror, M.; Saber, W.; Logan, B. R.; Geller, N.; Bellach, A.; Kou, J.; Wood, W. A.; McCarty, J. M.; Knight, T. G.; Runaas, L.; more...
    Blood (2024)

    Fulltext@MSK | Save